GlassScriptPhysician profile
Shazia Khan
NPI 1164526323
$1,253.48
in general payments reported to CMS, 2019-2025
22 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $119 · 2021: $66.04 · 2022: $108 · 2023: $79.24 · 2024: $271 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $85.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.49 |
| Education | $85.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.86 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $159.79 | 2019-2025 | Krystexxa, Aranesp, Tavneos |
| Otsuka America Pharmaceutical, INC. | $138.99 | 2019-2025 | Jynarque |
| Vantive US Healthcare LLC | $105.28 | 2025 | Renal - Pd |
| Novartis Pharmaceuticals Corporation | $101.68 | 2023-2025 | |
| Travere Therapeutics, INC. | $73.59 | 2020-2025 | Filspari |
| Vifor Pharma, INC. | $54.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.77 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $49.93 | 2020 | |
| Akebia Therapeutics INC | $44.96 | 2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $42.11 | 2022-2025 | |
| Horizon Therapeutics Plc | $37.17 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $34.90 | 2019 | |
| Calliditas Therapeutics US INC. | $26.87 | 2024 | |
| Cormedix INC. | $24.08 | 2024 | Defencath |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.54 | 2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $21.10 | 2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $20.46 | 2021 | |
| Ardelyx, INC. | $19.73 | 2025 | Ibsrela |
| Novo Nordisk INC | $16.35 | 2025 | Ozempic |
| Ani Pharmaceuticals, INC. | $15.40 | 2023 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shazia Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.